Thermo Fisher Acquires Novasep’s Viral Vector Mfg Business for $875 M
Thermo Fisher Scientific has completed the acquisition of Henogen S.A., Novasep’s viral vector manufacturing business in Belgium, for approximately EUR 725 million ($875 million).
Novasep’s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies with more than 7,000 square meters of clinical and commercial manufacturing capacity. The business has two locations in Seneffe and Gosselies, Belgium and has approximately 400 employees. It had estimated 2020 revenue of EUR 80 million ($96 million).
The business will be part of Thermo Fisher’s Pharma Services business within the Laboratory Products and Services Segment.
Source: Thermo Fisher Scientific and Novasep
